Clinical Trial Update: Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Co-administered With an Hepatitis A Virus Vaccine [Phase 3]

View source ↗

Summary

Phase 3 trial update showing immunogenicity and safety of co-administering a tetravalent dengue vaccine with a Hepatitis A vaccine in healthy volunteers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dengue Fever
• Hepatitis A

Drugs mentioned

• TDV (tetravalent dengue vaccine)

Snippet

Sponsor: Takeda | Conditions: Healthy Volunteers | Phase 3 | Status: COMPLETED | Results posted: 2020-07-13